A 45-year old with polycythemia vera not responding to hydroxyurea

Srdan Verstovsek, MD, PhD of the MD Anderson Cancer Center in Houston, Texas discusses a middle aged man with polychthemia vera who did not respond to initial therapy (hydroxurea) with and required another treatment option. One such option is ruxolitinib which is approved for treatment of polychthemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea.